Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Cytokine PharmaSciences |
---|---|
Information provided by: | Cytokine PharmaSciences |
ClinicalTrials.gov Identifier: | NCT00828711 |
Randomized, double blind, dose ranging study to assess the efficacy and safety of up to 24 hours treatment with the MVI 100, MVI 150 and MVI 200. Oxytocin may be used after removal of the study medication. There must be at least a 30 minute waiting interval between removing the study drug and commencing oxytocin. Patients will be stratified by parity and center. During treatment, women will be assessed for safety, onset of labor, and cervical ripening. Fetal heart rate patterns and uterine activity will be assessed via continuous CTG monitoring. Time to and mode of delivery of the neonate will be recorded. Modified Bishop score will be assessed at 6, 12, 18 and 24 hours after study drug insertion.
Condition | Intervention | Phase |
---|---|---|
Cervical Ripening Induction of Labor |
Drug: MVI 100 Drug: MVI 150 Drug: MVI 200 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Dose Comparison, Parallel Assignment, Efficacy Study |
Official Title: | A Multicenter, Randomized, Double-Blind, Dose-Ranging, Phase II Study to Assess the Efficacy and Safety of the 100, 150 and 200 Mcg Misoprostol Vaginal Insert for Women Requiring Cervical Ripening and Induction of Labor |
Estimated Enrollment: | 360 |
Study Start Date: | April 2009 |
Estimated Study Completion Date: | February 2010 |
Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
MVI 100 mcg vaginal insert
|
Drug: MVI 100
Hydrogel polymer vaginal insert with retrieval system, one 100 mcg insert for induction of labor, kept in place a maximum of 24h.
|
2: Experimental
MVI 150 mcg vaginal insert
|
Drug: MVI 150
Hydrogel polymer vaginal insert with retrieval system, one 150 mcg insert for induction of labor, kept in place a maximum of 24h.
|
3: Experimental
MVI 200 mcg vaginal insert
|
Drug: MVI 200
Hydrogel polymer vaginal insert with retrieval system, one 200 mcg insert for induction of labor, kept in place a maximum of 24h.
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
United States, Arizona | |
Precision Trials | |
Phoenix, Arizona, United States, 85032 | |
Tuscon Medical Center | |
Tucson, Arizona, United States, 85716 | |
United States, California | |
Long Beach Memorial Medical Center | |
Long Beach, California, United States, 90806 | |
UCI Medical Center | |
Orange, California, United States, 92868 | |
Santa Clara Valley Medical Center | |
San Jose, California, United States, 95128 | |
United States, Colorado | |
Exempla St. Joseph Hospital | |
Denver, Colorado, United States, 80218 | |
United States, New Mexico | |
University of New Mexico Medical Center | |
Albuquerque, New Mexico, United States, 87131 | |
United States, North Carolina | |
Forsyth Medical Center | |
Winston-Salem, North Carolina, United States, 27103 | |
Duke University Medical Center | |
Durham, North Carolina, United States, 27710 | |
United States, Pennsylvania | |
Temple University Hospital | |
Philadelphia, Pennsylvania, United States, 19140 | |
United States, South Carolina | |
Greenville Hospital System | |
Greenville, South Carolina, United States, 29605 | |
Trident Health System | |
North Charleston, South Carolina, United States, 29406 | |
United States, Tennessee | |
University of Tennesse Medical Center | |
Knoxville, Tennessee, United States, 37920 | |
Memphis, Tennessee, United States, 38119 | |
United States, Texas | |
University of Texas Health Sciences Center at Houston | |
Houston, Texas, United States, 77030 |
Principal Investigator: | William F Rayburn, MD | University of New Mexico |
Responsible Party: | Cytokine PharmaSciences, Inc. ( Barbara Powers ) |
Study ID Numbers: | Miso-Obs-204 |
Study First Received: | January 22, 2009 |
Last Updated: | July 29, 2009 |
ClinicalTrials.gov Identifier: | NCT00828711 History of Changes |
Health Authority: | United States: Food and Drug Administration |
Misoprostol vaginal insert Induction of labor Cervical ripening Rate of cesarean section |
Misoprostol |
Oxytocics Therapeutic Uses Anti-Ulcer Agents Physiological Effects of Drugs Abortifacient Agents |
Misoprostol Gastrointestinal Agents Reproductive Control Agents Abortifacient Agents, Nonsteroidal Pharmacologic Actions |